Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1969 1
1970 1
1971 1
1972 1
1973 1
1974 3
1975 4
1976 8
1977 5
1978 2
1979 5
1980 6
1981 10
1982 1
1983 2
1984 2
1985 6
1986 12
1987 9
1988 3
1989 13
1990 14
1991 13
1992 7
1993 6
1994 4
1995 10
1996 10
1997 6
1998 10
1999 10
2000 12
2001 10
2002 9
2003 11
2004 10
2005 12
2006 12
2007 20
2008 13
2009 12
2010 13
2011 13
2012 13
2013 5
2014 15
2015 7
2016 11
2017 9
2018 10
2019 12
2020 5
2021 10
2022 11
2023 11
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

417 results

Results by year

Filters applied: . Clear all
Page 1
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group. Howard JF Jr, et al. Among authors: garrido fjrr. Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22. Neurology. 2019. PMID: 31118245 Free PMC article. Clinical Trial.
Introduction.
Garrido F. Garrido F. Adv Exp Med Biol. 2019;1151:1-14. doi: 10.1007/978-3-030-17864-2_1. Adv Exp Med Biol. 2019. PMID: 31140105 Review.
HLA Class-II Expression in Human Tumors.
Garrido F. Garrido F. Adv Exp Med Biol. 2019;1151:91-95. doi: 10.1007/978-3-030-17864-2_4. Adv Exp Med Biol. 2019. PMID: 31140108 Review.
The Role of Chemokines in Cervical Cancers.
Garrido F, Wild CM, Mittelberger J, Dobler F, Schneider M, Ansorge N, Köpke M, Strieder A, Ditsch N, Jeschke U, Dannecker C. Garrido F, et al. Medicina (Kaunas). 2021 Oct 21;57(11):1141. doi: 10.3390/medicina57111141. Medicina (Kaunas). 2021. PMID: 34833360 Free PMC article. Review.
MHC/HLA Class I Loss in Cancer Cells.
Garrido F. Garrido F. Adv Exp Med Biol. 2019;1151:15-78. doi: 10.1007/978-3-030-17864-2_2. Adv Exp Med Biol. 2019. PMID: 31140106 Review.
MHC heterogeneity and response of metastases to immunotherapy.
Algarra I, Garrido F, Garcia-Lora AM. Algarra I, et al. Among authors: garrido f. Cancer Metastasis Rev. 2021 Jun;40(2):501-517. doi: 10.1007/s10555-021-09964-4. Epub 2021 Apr 15. Cancer Metastasis Rev. 2021. PMID: 33860434 Review.
Rejection versus escape: the tumor MHC dilemma.
Garrido F, Ruiz-Cabello F, Aptsiauri N. Garrido F, et al. Cancer Immunol Immunother. 2017 Feb;66(2):259-271. doi: 10.1007/s00262-016-1947-x. Epub 2016 Dec 31. Cancer Immunol Immunother. 2017. PMID: 28040849 Review.
417 results